WSJ -- Getting Closer: Sanofi-Aventis and Genzyme are inching towards a deal, with the French pharma company proposing to pay around $74 per share for the Boston biotech plus additional payments linked largely to the performance of a potential MS treatment, the WSJ reports, citing people familiar with the matter.
